Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Rong Tao
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07493109CT.gov Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP | — | Recruiting | — | — | — |
NCT07493148CT.gov Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL | — | Recruiting | — | — | — |
NCT07415980CT.gov Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL | — | Not Yet Recruiting | — | — | — |
NCT07397832CT.gov CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL | — | Recruiting | — | — | — |
NCT07538180CT.gov Serplulimab, Chidamide, and Rituximab Followed by Sequential R-CHOP for Newly Diagnosed Elderly MYC/BCL2 Double-Expressor DLBCL | — | Active Not Recruiting | — | — | — |
NCT06890585CT.gov Zanubrutinib, Chidamide, and Rituximab Induction With or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCL | — | Not Yet Recruiting | — | — | — |
NCT06758037CT.gov Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients With DLBCL Intolerant to Chemotherapy | — | Recruiting | — | — | — |
NCT06748521CT.gov Dynamic CtDNA-guided Targeted Therapy in DLBCL | — | Not Yet Recruiting | — | — | — |
NCT06750991CT.gov CD-RCHOP in ND DLBCL With a Combination of TP53 Mutation and Del(17p) | — | Not Yet Recruiting | — | — | — |
NCT06701357CT.gov CR-CHOP+X in Previously Untreated DEL | — | Recruiting | — | — | — |
Show 14 more trialsShow fewer
NCT06516978CT.gov A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL | — | Not Yet Recruiting | — | — | — |
NCT06891157CT.gov Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes | — | Recruiting | — | — | — |
NCT05784987CT.gov R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | — | Unknown | — | — | — |
NCT05527912CT.gov A Phase II Study of Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy | — | Unknown | — | — | — |
NCT05823701CT.gov Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients | — | Unknown | — | — | — |
NCT05466318CT.gov ChiCGB vs BEAM in High-risk or R/R Lymphomas | — | Unknown | — | — | — |
NCT05348213CT.gov Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma | — | Recruiting | — | — | — |
NCT04231448CT.gov Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL | — | Completed | — | — | — |
NCT04025593CT.gov Biomarker Guided Treatment in DLBCL | — | Unknown | — | — | — |
NCT04022005CT.gov Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL | — | Completed | — | — | — |
NCT03629873CT.gov Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects | — | Unknown | — | — | — |
NCT03373019CT.gov Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | — | Unknown | — | — | — |
NCT04661943CT.gov Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma | — | Completed | — | — | — |
NCT02733380CT.gov Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Diffuse Large B-Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tucidinostat (this asset) | Rong Tao | P3 | BB · 65 |
| Vincristine Sulfate | National Cancer Institute (NCI) | P2/3 | A |
| Melphalan | Ruijin Hospital | P4 | BBB |
| Axicabtagene Ciloleucel | Ruijin Hospital | P4 | BBB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P3 | BBB |
| Nivestim | Ruijin Hospital | P3 | BBB |
| Prednisone | Beth Israel Deaconess Medical Center | P4 | BBB |
| Adriamycin | Beth Israel Deaconess Medical Center | P4 | BBB |
| Rituximab | Beth Israel Deaconess Medical Center | P4 | BBB |
+42 more in the Diffuse Large B-Cell Lymphoma cohort
Other indications for Tucidinostat
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Extranodal Nasal NK/T Cell Lymphoma | — | P4 | BB · 70 |
| Peripheral T-Cell Lymphoma, Not Otherwise Specified | — | P4 | BB · 69 |
| Acute Lymphoblastic Leukemia | — | P2/3 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tucidinostat in Diffuse Large B-Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tucidinostat-diffuse-large-b-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →